Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolastin PET/CT study of pulmonary neutrophilic inflammation in alpha-1 antitrypsin deficiency
2007-004869-18Phase 2Completed
- Sponsor
- University Hospitals Birmingham
- Start
- Apr 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of alpha-1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD) and emphysema (3 cohorts), sponsored by University Hospitals Birmingham. Primary endpoints: Global pulmonary neutrophilic inflammation, Within-patient change in PET/CT inflammation signal and 1 more. Started Apr 2008; status: completed.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)emphysema
Beyond the preview
Go deeper on 2007-004869-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004869-18.